Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $75.00 short call and a strike $80.00 long call offers a potential 14.94% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $75.00 by expiration. The full premium credit of $0.65 would be kept by the premium seller. The risk of $4.35 would be incurred if the stock rose above the $80.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is at 33.51 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
8:32 am Gilead Sciences issues Notice of Compliance from Health Canada for Sovaldi for the treatment of chronic Hepatitis C; Sovaldi Receives Marketing Authorization for patients with genotypes 1, 2, 3 or 4 HCV
Mon, 16 Dec 2013 23:06:09 GMT
Briefing.com – 8:32 am Gilead Sciences issues Notice of Compliance from Health Canada for Sovaldi for the treatment of chronic Hepatitis C; Sovaldi Receives Marketing Authorization for patients with genotypes 1, 2, 3 or 4 HCV
Business Highlights
Mon, 16 Dec 2013 22:01:54 GMT
AP – ___ US economy grows at 3.6 percent rate in 3rd quarter The U.S. economy grew at a 3.6 percent annual rate from July through September, the fastest since early 2012. But nearly half the growth came from …
Label of Gilead's Complera Expanded
Mon, 16 Dec 2013 16:00:04 GMT
Zacks – The label of Complera has been expanded.
Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Mon, 16 Dec 2013 13:30:00 GMT
Business Wire – Gilead Sciences, Inc. today announced that Health Canada has issued a Notice of Compliance for Sovaldi™ 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C infection.
Hep C Price War? Abbvie Vs. Gilead
Mon, 16 Dec 2013 11:08:49 GMT
Seeking Alpha – The new hepatitis C pills may become some of the biggest pharmaceutical sellers ever. Gilead's ( GILD ) Sovaldi (generically known as sofosbuvir) was approved on December 6 by the FDA to treat certain …
Related Posts
Also on Market Tamer…
Follow Us on Facebook